The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer

NCT00619242 · clinicaltrials.gov ↗

NA

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

Esophageal Cancer

Interventions

DRUG: sorafenib

Sponsor

University of Chicago

Collaborators

[object Object]